These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26363436)

  • 1. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
    Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
    Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.
    Sorci-Thomas MG; Zabalawi M; Bharadwaj MS; Wilhelm AJ; Owen JS; Asztalos BF; Bhat S; Thomas MJ
    Biochim Biophys Acta; 2012 Mar; 1821(3):502-12. PubMed ID: 21944998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochemistry; 2007 Sep; 46(37):10713-21. PubMed ID: 17711302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma.
    Miccoli R; Zhu Y; Daum U; Wessling J; Huang Y; Navalesi R; Assmann G; von Eckardstein A
    J Lipid Res; 1997 Jun; 38(6):1242-53. PubMed ID: 9215551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice.
    Chroni A; Kan HY; Shkodrani A; Liu T; Zannis VI
    Biochemistry; 2005 Mar; 44(10):4108-17. PubMed ID: 15751988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.
    Zamanian-Daryoush M; Gogonea V; DiDonato AJ; Buffa JA; Choucair I; Levison BS; Hughes RA; Ellington AD; Huang Y; Li XS; DiDonato JA; Hazen SL
    J Biol Chem; 2020 Apr; 295(15):4836-4848. PubMed ID: 32098873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders.
    Daniil G; Phedonos AA; Holleboom AG; Motazacker MM; Argyri L; Kuivenhoven JA; Chroni A
    Clin Chim Acta; 2011 Jun; 412(13-14):1213-20. PubMed ID: 21420943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
    Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
    Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.
    Cukier AMO; Therond P; Didichenko SA; Guillas I; Chapman MJ; Wright SD; Kontush A
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):890-900. PubMed ID: 28529180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
    Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
    Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Natural LCAT Mutations on the Biogenesis of HDL.
    Fotakis P; Kuivenhoven JA; Dafnis E; Kardassis D; Zannis VI
    Biochemistry; 2015 Jun; 54(21):3348-59. PubMed ID: 25948084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
    Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo.
    Chroni A; Koukos G; Duka A; Zannis VI
    Biochemistry; 2007 May; 46(19):5697-708. PubMed ID: 17447731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arg123-Tyr166 domain of human ApoA-I is critical for HDL-mediated inhibition of macrophage homing and early atherosclerosis in mice.
    Holvoet P; Peeters K; Lund-Katz S; Mertens A; Verhamme P; Quarck R; Stengel D; Lox M; Deridder E; Bernar H; Nickel M; Theilmeier G; Ninio E; Phillips MC
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1977-83. PubMed ID: 11742873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism.
    Hedrick CC; Hassan K; Hough GP; Yoo JH; Simzar S; Quinto CR; Kim SM; Dooley A; Langi S; Hama SY; Navab M; Witztum JL; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1946-52. PubMed ID: 10938016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using adenovirus-mediated gene transfer to study the effect of myeloperoxidase on plasma lipid levels, HDL structure and functionality in mice expressing human apoA-I forms.
    Dalakoura-Karagkouni K; Tiniakou I; Zannis VI; Kardassis D
    Biochem Biophys Res Commun; 2022 Sep; 622():108-114. PubMed ID: 35843089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
    Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
    Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.